Clinical NGS All-in-One Solution Provider, NGeneBio started as KT’s internal corporate venture in 2010. KT’s ICT & Big Data technology combined with precision medicine platform technology to develop the nation’s first “massive genomics platform” which led to the foundation of NGeneBio as an independent company in October 2015. The company launched an NGS-based hereditary breast/ovarian cancer panel (BRCAaccuTest™ PLUS) with clinical analysis S/W (NGeneAnalySys™) and received CE-IVD and KFDA approval in 2017. Additionally, the company also launched NGS panels and SW for solid tumors (SOLIDaccuTest™) and hematological malignancies (HEMEaccuTest™, CE-IVD marked in 2018). ONCOaccuPanel™ is a comprehensive cancer panel capable of identifying various genetic mutations and immunotherapy biomarkers (TMB, MSI) in solid tumors with analysis software 'NGeneAnalySys™'. Additionally, based on NGS technology HLAaccuTest™ is an NGS panel for HLA (human leukocyte antigen) typing that can identify high-resolution histocompatibility antigens with analysis software EasyHLAanalyzer™. We have been working on research and development with the cooperation of the anticancer diagnosis project team, domestic and foreign hospitals, and biotech companies. We have been striving to secure the technology and develop a business model of mid-to-long-term perspectives through external patent license-in in addition to the company’s own patent discovery. We are doing our utmost to achieve our goal of a global healthcare service provider based on four core values of challenging execution, respect for life, human resource development, and customer trust, and we look forward to your continued support and interest.